重型先天性中性白细胞减少症
Severe congenital neutropenia
定义 英文原文(暂无中文)
A rare primary immunodeficiency, without an associated lymphocyte deficit, characterized by impaired neutrophil maturation and/or function, associated with severe infections, diverse comorbidities, and/or an increased risk of leukemic transformation.
基本事实
- 遗传方式
- 常染色体显性、常染色体隐性、X 连锁隐性
- 发病年龄
- 儿童期
- 患病率
- 1-9 / 1 000 000(Europe)
相关基因 13来自下位疾病
Orphanet 未在本条目上直接标注致病基因。下表由本组所属的下位疾病汇总而来,「来源条目」列给出基因实际标注在哪一个 ORPHA 条目上。
| 基因 | 名称 | 来源条目 |
|---|---|---|
| CLPB | ClpB family mitochondrial disaggregase | ORPHA:486 |
| CSF3R | colony stimulating factor 3 receptor | ORPHA:420702 |
| CXCR2 | C-X-C motif chemokine receptor 2 | ORPHA:420699 |
| ELANE | elastase, neutrophil expressed | ORPHA:486 |
| G6PC3 | glucose-6-phosphatase catalytic subunit 3 | ORPHA:331176 |
| GFI1 | growth factor independent 1 transcriptional repressor | ORPHA:486 |
| HAX1 | HCLS1 associated protein X-1 | ORPHA:99749 |
| JAGN1 | jagunal vesicle mediated transporter 1 | ORPHA:423384 |
| SRP19 | signal recognition particle 19 | ORPHA:486 |
| SRP54 | signal recognition particle 54 | ORPHA:675767 |
| TCIRG1 | T cell immune regulator 1, ATPase H+ transporting V0 subunit a3 | ORPHA:486 |
| VPS45 | vacuolar protein sorting 45 homolog | ORPHA:369852 |
| WAS | WASP actin nucleation promoting factor | ORPHA:86788 |
近两年的全球研究 243L2
2024/10 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。
- 2026-10开放获取Proteomic Signatures of Noise-Induced Hearing Loss in the Mouse Cochlea
- 2026-09Clinical outcome and infectious complications in genetic and suspected genetic neutropenia: A report from the Canadian Inherited Marrow Failure Registry
- 2026-09开放获取GTPase cycle and ER membrane regulate cargo handover during cotranslational protein targeting
- 2026-09A yeast model for the functional analysis of SRP54 mutations associated with severe congenital neutropenia
- 2026-09病例报告开放获取A Rare Case of Neonatal-Onset Diarrhea Due to Congenital Tufting Enteropathy: Clinical, Histopathological, and Genetic Insights
- 2026-09Facial Phenotypic Pattern in Severe Congenital Neutropenia Type 4 (G6PC3 Deficiency): Description and Clinical Value
- 2026-09Jagunal homolog 1 safeguards neutrophil immune function by preserving protein sialylation during differentiation
- 2026-08病例报告开放获取Early-Onset TRNT1-Related SIFD Syndrome with an Additional Monoallelic C7 Variant: A Pediatric Case Report
- 2026-08病例报告开放获取Prenatal diagnosis of glucose-6-phosphatase catalytic subunit 3 deficiency (Dursun syndrome) using whole-exome sequencing: A case report of severe fetal cardiomyopathy in a consanguineous family
- 2026-08综述开放获取Innate immunity: current understandings and future perspectives
- 2026-08开放获取Wiskott-Aldrich syndrome: clinical, immunological, and genetic characterization of the first Moroccan cohort
- 2026-08综述Clinical pearls and pitfalls in inborn errors of immunity: An expert-derived framework for diagnostic pattern recognition
- 2026-08开放获取COPZ1 depletion induces cell death through different mechanisms in in vitro murine models of thyroid cancer
- 2026-08TCR-αβ/CD 19 Depleted Graft Versus T Replete Graft With Post-Transplant Cyclophosphamide in Children Undergoing Haploidentical Donor Hematopoietic Stem Cell Transplantation for Inborn Errors of Immunity: A Comparative Analysis From India
- 2026-07开放获取Clinical benefit, price and epidemiology of orphan drugs approved in China: a cross-sectional analysis of orphan drug policy (ODP) in China
- 2026-07开放获取Targeting the HPV E6-p53 degradation axis via computational and <i>in vitro</i> identification of a repurposed small-molecule candidate
- 2026-07综述开放获取Splenectomy revisited in Wiskott-Aldrich syndrome in the era of HSCT and gene therapy: a bridge, a rescue, or simply obsolete?
- 2026-07开放获取J2R/F4L deleted oncolytic vaccinia virus synergizes with tumor specific killer (ELANE) promotes antitumor immunity with superior safety
- 2026-07病例报告开放获取Palatal Perforation as a Rare Presentation of Severe Congenital Neutropenia Due to an ELANE Mutation
- 2026-07综述开放获取Fungal Infections in Disorders of Inborn Errors of Immunity
境外已获批用于本病的药物 0L2
欧盟与美国均未检索到已获批用于本病的药物。
尚未获批的在研药物(1 项)
这些药已被欧盟或美国的监管机构认定为罕见病用药(英文 orphan drug designation,中文行业里通称「孤儿药资格」——「孤儿」说的是这类药市场太小、没有厂商愿意认领,不是在说病人)。但这只是一种监管身份:意味着监管机构给予研发上的激励,不代表这个药已被证明有效,也不代表将来一定能上市,绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
- mavorixafor美国2026-08-26该药获批用于体质性中性粒细胞减少症,本病属于其中treatment of congenital neutropenia官方记录
数据来自欧洲药品管理局(EMA)的药品与罕见病用药资格公开导出表,以及美国 FDA 的罕见病用药资格数据库(Orphan Drug Product Designation Database)。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。
中国境外的在招试验 5L2
这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。
共 5 项。
- 招募中NCT07066085Serial Blood Count Study美国
- 招募中NCT06056297A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections阿根廷、澳大利亚、比利时、加拿大、哥伦比亚、捷克、法国、Georgia 等 25 国
- 招募中NCT06999954Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform美国
- 招募中NCT04099966AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion美国
- 招募中NCT02720679Investigation of the Genetics of Hematologic Diseases美国
外部标识与链接
发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
- 中文病名:Orphanet 中文包,冻结于 2020-06-01
- 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)